Can CoolSculpting Remove Visceral Fat?

Can CoolSculpting remove visceral fat? It is a question worth asking carefully, because the answer has real implications for health. CoolSculpting (cryolipolysis) is a popular non-invasive body contouring treatment that uses controlled cooling to reduce localised fat, but not all fat is the same. Visceral fat, stored deep around the organs, carries significant metabolic risk and behaves very differently from the subcutaneous fat just beneath the skin. Understanding what CoolSculpting can and cannot do is essential before choosing any treatment aimed at improving body composition or reducing health risk.

What is the difference between visceral fat and subcutaneous fat?

Visceral fat is stored deep within the abdominal cavity around the organs and is metabolically active, raising the risk of type 2 diabetes and cardiovascular disease, whereas subcutaneous fat sits just beneath the skin and is generally less harmful.

Visceral fat and subcutaneous fat are two distinct types of body fat that differ fundamentally in their location, behaviour, and health implications. Subcutaneous fat sits directly beneath the skin and can be pinched between the fingers. It is distributed across the abdomen, thighs, hips, and upper arms, and while excess amounts are associated with metabolic risk, it is generally considered less harmful than its deeper counterpart.

Visceral fat, by contrast, is stored deep within the abdominal cavity, surrounding internal organs such as the liver, pancreas, and intestines. It is metabolically active in a way that subcutaneous fat is not, releasing inflammatory cytokines and free fatty acids directly into the portal circulation.^[1][2] Higher levels of visceral fat are associated with an increased risk of type 2 diabetes, cardiovascular disease, and certain cancers, as described in NHS guidance on healthy weight.^[3]

The two fat types also respond differently to lifestyle interventions. Evidence suggests that visceral fat tends to be more responsive to dietary change and aerobic exercise than subcutaneous fat, though individual responses vary.

Waist circumference is commonly used as a clinical proxy for visceral fat burden. NICE guidance notes that a waist measurement above 88 cm in women and above 102 cm in men indicates substantially increased metabolic risk, though these thresholds are not universal: risk begins at lower waist measurements in people of South Asian, Chinese, Japanese, and some other ethnic backgrounds.^[4] Current NICE guidance also recommends considering waist-to-height ratio as a complementary measure, with a ratio below 0.5 generally indicating lower cardiometabolic risk across a broader range of ethnic groups.

Understanding this distinction is clinically important because treatments that target one type of fat do not necessarily affect the other. A procedure that reduces a visible pinch of subcutaneous fat may have no meaningful impact on the deeper visceral deposits that carry the greatest health risk.

How does CoolSculpting actually work on fat tissue?

CoolSculpting uses controlled cooling to trigger apoptosis in subcutaneous fat cells, which are then cleared by the immune system over several weeks. It is a body contouring procedure, not a weight-loss treatment.

CoolSculpting (cryolipolysis) works by applying controlled cooling to a targeted area of the body, reducing the temperature of fat cells to a point that triggers their natural death without damaging the overlying skin. The device uses applicators that draw a fold of tissue into a cup-shaped handpiece, where temperatures are lowered to sub-zero levels. Fat cells are more susceptible to cold-induced injury than surrounding skin, nerve, and muscle tissue, a principle known as selective cryolysis.^[7][8]

Once cooled to this threshold, fat cells undergo a process called apoptosis, a form of programmed cell death. Over the following weeks, the body's immune system gradually clears the dead cells through the lymphatic system. Clinical studies suggest that a single treatment session can produce a measurable reduction in the fat layer in the treated area, though individual results vary and multiple sessions are often recommended by practitioners.

The procedure is non-invasive and does not require anaesthesia or incisions. Common side effects include temporary redness, bruising, numbness, and tingling at the treatment site, which generally resolve within days to weeks.

Cryolipolysis is not suitable for everyone. It is contraindicated in people with conditions that increase sensitivity to cold, including cryoglobulinaemia, cold agglutinin disease, and paroxysmal cold haemoglobinuria.^[8] Anyone considering the procedure should be assessed by a suitably qualified clinician beforehand to confirm it is appropriate for them.

It is important to note that CoolSculpting is a body contouring procedure, not a weight-loss treatment. It is designed to reduce localised pockets of fat in people who are already close to their target weight, and it is not a substitute for lifestyle modification or medically supervised weight management. CoolSculpting devices used in the UK must meet applicable MHRA regulatory standards before clinical use.

Can CoolSculpting reach the fat stored deep around your organs?

CoolSculpting cannot reach visceral fat because its cooling only penetrates the subcutaneous layer, a few centimetres beneath the skin, and cannot pass through the muscle and connective tissue separating it from the organs.

CoolSculpting cannot remove visceral fat, because the cooling technology only penetrates the superficial layers of tissue and cannot reach the fat stored deep within the abdominal cavity. The applicators work by drawing a fold of skin and subcutaneous tissue into contact with cooling panels. The depth of effective cooling is limited to the subcutaneous layer, which typically extends no more than a few centimetres beneath the skin surface. Visceral fat lies far beyond this reach, separated from the skin by layers of muscle and connective tissue.

This is not a limitation unique to CoolSculpting. No non-invasive external body contouring device currently available is capable of selectively targeting visceral fat. Even surgical procedures such as liposuction, which physically removes fat, are restricted to the subcutaneous compartment and do not address visceral deposits.^[13][14] Reducing visceral fat requires systemic interventions that alter the body's overall energy balance and metabolic environment.

The most evidence-based approaches to reducing visceral fat include sustained caloric deficit through dietary change and regular aerobic exercise, particularly at moderate to vigorous intensity. Where clinically indicated, pharmacological treatment may also be considered. Semaglutide (Wegovy) and tirzepatide (Mounjaro) are both MHRA-authorised in the UK for chronic weight management and have been shown in clinical trials to reduce total body fat, including visceral fat, as part of broader weight loss.^[10][11] Access to these medicines on the NHS follows NICE guidance and is subject to local Integrated Care Board commissioning and specialist pathway criteria; eligibility requirements apply. Bolt Pharmacy is a GPhC-registered online pharmacy offering weight-management consultations with prescriber review and pharmacist support, where clinically appropriate options may be considered alongside lifestyle advice.

Patients concerned about visceral fat accumulation should speak to their GP, who can assess cardiovascular and metabolic risk and recommend an appropriate management plan.

What does the evidence say about CoolSculpting and body fat reduction?

Clinical evidence supports CoolSculpting for reducing localised subcutaneous fat, but no robust evidence shows it reduces visceral fat, improves insulin sensitivity, or lowers cardiovascular risk markers.

The clinical evidence supports CoolSculpting as an effective method for reducing localised subcutaneous fat, but does not support its use as a tool for reducing visceral fat or achieving meaningful overall weight loss. Systematic reviews of cryolipolysis, including work published in the Aesthetic Surgery Journal, have found statistically significant reductions in subcutaneous fat thickness in treated areas, with patient satisfaction rates generally reported as high.^[8][9] However, the studies reviewed were predominantly short-term, involved relatively small sample sizes, and focused on cosmetic outcomes rather than metabolic health markers.

Importantly, no robust clinical evidence demonstrates that CoolSculpting reduces visceral fat volume, improves insulin sensitivity, lowers cardiovascular risk markers, or produces the kind of metabolic benefits associated with meaningful weight loss. These outcomes require reductions in total body fat mass, particularly visceral fat, which CoolSculpting is not designed or able to achieve.

A rare but recognised adverse effect of cryolipolysis is paradoxical adipose hyperplasia, a condition in which the treated area develops a firm, enlarged mass of fat tissue rather than reducing. This occurs more commonly in male patients and in certain anatomical areas, and may require surgical correction. Patients should be counselled about this risk before undergoing treatment. Suspected adverse effects from any medical device or medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

For individuals whose primary concern is health rather than cosmetic contouring, the evidence base strongly favours lifestyle intervention and, where appropriate, clinically supervised pharmacological treatment over body contouring procedures. Anyone experiencing unexplained weight gain, a rapidly increasing waist circumference, or associated symptoms such as fatigue or elevated blood pressure should consult their GP rather than seeking a cosmetic procedure.

Frequently Asked Questions